



ADULT MEDICATION GUIDELINE

CEFAZOLIN

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Anti-infective – Cephalosporin

Presentation

Vial: 1g, 2g

Storage

Store at room temperature, below 25°C. Protect from light

Dose

Surgical prophylaxis

Refer to KEMH Clinical Practice Guidelines: O&G:

[Infections \(obstetrics and gynaecological\): Antibiotic prophylaxis for caesarean section](#)

[Infections: Antibiotic prophylaxis for gynaecology and urogynaecology surgery](#)

Intrapartum Group B Streptococcus prophylaxis (non-severe penicillin hypersensitivity):

Refer to KEMH Clinical Practice Guideline: O&G: [Group B Streptococcal Disease](#)

Mastitis and breast abscess

Refer to KEMH Clinical Practice Guideline: O&G: [Mastitis and breast abscess management](#)

Perineal Care and repair

Refer to KEMH Clinical Practice Guideline: O&G: [Perineal care and repair](#)

Prophylaxis for operative vaginal delivery (non-severe penicillin hypersensitivity)

To minimise neonatal exposure, only administer AFTER cord clamping

IV:

2g (as a single dose) within 6 hours of delivery, in conjunction with other agents. Refer to KEMH Clinical Practice Guideline: O&G: [Operative Vaginal Birth](#)

Administration

Refer to the [Australian Injectable Drugs Handbook](#).

Monitoring

Monitor complete blood count, hepatic and renal function during prolonged treatment

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

Breastfeeding

Considered safe to use

Related Policies, Procedures & Guidelines**WNHS Policy:**

[Antimicrobial Stewardship](#)

WNHS Clinical Practice Guidelines:

[Group B Streptococcal Disease](#)

[Infections \(obstetrics and gynaecological\): Antibiotic prophylaxis for Caesarean section](#)

[Infections: Antibiotic prophylaxis for gynaecology and urogynaecology surgery](#)

[Mastitis and breast abscess management](#)

[Perineal care and repair: Protection, assessment and management](#)

[Operative Vaginal Birth](#)

[Prescribing by Eligible Private Practicing Midwives \(EPPM\)](#)

[Increased Body Mass Index: management of a woman with](#)









References

Australian Medicines Handbook. Cefazolin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Aug 18]. Available from: <https://amhonline.amh.net.au/>

Society of Hospital Pharmacists of Australia. Cefazolin . In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Aug 18]. Available from: <http://aidh.hcn.com.au>

Therapeutic Guidelines. Cross-reactivity between betalactams. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines Antibiotic V15; 2021 [cited 2021 Aug 18]. Available from: <https://tgldcdp.tg.org.au>

The Royal Women's Hospital. Cefazolin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Aug 18]. Available from: <https://thewomenspbmg.org.au/>

Keywords	Cefazolin, mastitis, caesarean section, surgical prophylaxis, gynaecological prophylaxis, cephalosporin, GBS, Group B Streptococcus				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	Mar 2019: full review Aug 2021: Update doses for Group B streptococcal Disease				
Date First Issued:	Jan 2015	Last Reviewed:	Aug 2021	Review Date:	Aug 2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	Aug 2021
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.